LSE:INDV

Stock Analysis Report

Executive Summary

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence.

Snowflake

Fundamentals

Good value with acceptable track record.


Similar Companies

Share Price & News

How has Indivior's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

12.2%

INDV

-3.4%

GB Pharmaceuticals

1.9%

GB Market


1 Year Return

-71.8%

INDV

13.9%

GB Pharmaceuticals

2.4%

GB Market

Return vs Industry: INDV underperformed the UK Pharmaceuticals industry which returned 13.9% over the past year.

Return vs Market: INDV underperformed the UK Market which returned 2.4% over the past year.


Shareholder returns

INDVIndustryMarket
7 Day12.2%-3.4%1.9%
30 Day2.8%-0.08%-1.1%
90 Day25.1%5.6%-1.8%
1 Year-71.8%-71.8%17.3%13.9%7.4%2.4%
3 Year-82.7%-82.7%44.9%30.7%18.2%3.7%
5 Yearn/a84.9%54.5%35.7%6.1%

Price Volatility Vs. Market

How volatile is Indivior's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Indivior undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: INDV (£0.54) is trading below our estimate of fair value (£7.02)

Significantly Undervalued: INDV is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: INDV is good value based on its PE Ratio (2x) compared to the Pharmaceuticals industry average (20.4x).

PE vs Market: INDV is good value based on its PE Ratio (2x) compared to the UK market (16.5x).


Price to Earnings Growth Ratio

Low PEG Ratio: INDV's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: INDV is overvalued based on its PB Ratio (2.5x) compared to the GB Pharmaceuticals industry average (2.5x).


Next Steps

Future Growth

How is Indivior forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-37.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: INDV's earnings are forecast to decline over the next 3 years (-37.2% per year).

Earnings vs Market: INDV's earnings are forecast to decline over the next 3 years (-37.2% per year).

High Growth Earnings: INDV's earnings are forecast to decline over the next 3 years.

Revenue vs Market: INDV's revenue is expected to decline over the next 3 years (-6.2% per year).

High Growth Revenue: INDV's revenue is forecast to decline over the next 3 years (-6.2% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if INDV's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Indivior performed over the past 5 years?

-21.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: INDV's earnings have declined by -21.5% per year over the past 5 years.

Accelerating Growth: INDV's earnings growth over the past year (279.1%) exceeds its 5-year average (-21.5% per year).

Earnings vs Industry: INDV earnings growth over the past year (279.1%) exceeded the Pharmaceuticals industry 24.2%.


Return on Equity

High ROE: Whilst INDV's Return on Equity (123.9%) is outstanding, this metric is skewed due to their high level of debt.


Return on Assets

ROA vs Industry: INDV has a higher Return on Assets than the Pharmaceuticals industry average last year.


Return on Capital Employed

ROCE Improving: INDV's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is Indivior's financial position?


Financial Position Analysis

Short Term Liabilities: INDV's short term assets ($1.3B) exceeds its short term liabilities ($645.0M)

Long Term Liabilities: INDV's short term assets (1.3B) exceeds its long term liabilities (718.0M)


Debt to Equity History and Analysis

Debt Level: INDV's debt to equity ratio (116.6%) is considered high

Reducing Debt: Insufficient data to determine if INDV's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: INDV's debt is well covered by operating cash flow (115.1%).

Interest Coverage: Insufficient data to determine if INDV's interest payments on its debt are well covered by EBIT.


Balance Sheet

Inventory Level: INDV has a low level of unsold assets or inventory.

Debt Coverage by Assets: INDV's debt is covered by short term assets (assets are 5.317990x debt).


Next Steps

Dividend

What is Indivior's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

company0%marketbottom25%2.0%markettop25%5.4%industryaverage3.1%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate INDV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate INDV's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if INDV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if INDV's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: INDV is not paying a notable dividend for the UK market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of INDV's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

What is the CEO of Indivior's salary, the management and board of directors tenure and is there insider trading?

5.0yrs

Average management tenure


CEO

Shaun Thaxter 0

5.8yrs

Tenure

US$1,009,700

Compensation

Mr. Shaun Thaxter has been the Chief Executive Officer of Indivior PLC since 2014. Mr. Thaxter served as the President and Chief Executive Officer of Reckitt Benckiser Pharmaceuticals, Inc. since 2009. Mr. ...


CEO Compensation Analysis

Compensation vs. Market: Shaun's total compensation ($USD1.01M) is about average for companies of similar size in the UK market ($USD874.66K).

Compensation vs Earnings: Shaun's compensation has been consistent with company performance over the past year.


Management Age and Tenure

5.0yrs

Average Tenure

Experienced Management: INDV's management team is seasoned and experienced (5 years average tenure).


Board Age and Tenure

4.0yrs

Average Tenure

61yo

Average Age

Experienced Board: INDV's board of directors are considered experienced (4 years average tenure).


Insider Trading

Insider Buying: INDV insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$5,00013 Aug 19
Lorna Parker
EntityIndividual
Role
Member of the Board of Directors
Non-Executive Director
Shares8,282
Max PriceUS$0.60
BuyUS$32,77809 Aug 19
Peter James Bains
EntityIndividual
Role
Member of the Board of Directors
Independent Non-Executive Director
Shares54,000
Max PriceUS$0.61
BuyUS$9,94515 May 19
Tatjana May
EntityIndividual
Role
Member of the Board of Directors
Non-Executive Director
Shares22,309
Max PriceUS$0.45
BuyUS$44,64015 May 19
Shaun Thaxter
EntityIndividual
Role
Chief Executive Officer
CEO & Executive Director
Shares100,000
Max PriceUS$0.45
BuyUS$5,00013 May 19
Lorna Parker
EntityIndividual
Role
Member of the Board of Directors
Non-Executive Director
Shares11,529
Max PriceUS$0.43

Ownership Breakdown


Management Team

  • Jason Thompson

    Vice President of Investor Relations

    • Tenure: 0yrs
  • Shaun Thaxter

    CEO & Executive Director

    • Tenure: 5.8yrs
    • Compensation: US$1.01m
  • Cindy Cetani

    Chief Integrity & Compliance Officer

    • Tenure: 1yrs
  • Mark Crossley

    Chief Financial & Operations Officer and Executive Director

    • Tenure: 2.7yrs
    • Compensation: US$550.80k
  • Richard Simkin

    Chief Commercial & Strategy Officer

    • Tenure: 0yrs
  • Christian Heidbreder

    Chief Scientific Officer

    • Tenure: 0yrs
  • Javier Rodriguez

    Chief Legal Officer

    • Tenure: 0yrs
  • Debby Betz

    Chief Corporate Affairs & Communications Officer

    • Tenure: 5yrs
  • Jon Fogle

    Chief Human Resources Officer

    • Tenure: 5yrs
  • Frank Stier

    Chief Manufacturing & Supply Officer

    • Tenure: 5yrs

Board Members

  • Howard Pien (61yo)

    Independent Chairman

    • Tenure: 0yrs
  • Dan Phelan (69yo)

    Non-Executive Director

    • Tenure: 4.9yrs
  • Tatjana May (54yo)

    Non-Executive Director

    • Tenure: 2.7yrs
  • Peter James Bains (62yo)

    Independent Non-Executive Director

    • Tenure: 0.2yrs
  • Daniel Tassé (59yo)

    Senior Independent Director

    • Tenure: 3.1yrs
  • Shaun Thaxter

    CEO & Executive Director

    • Tenure: 5.8yrs
    • Compensation: US$1.01m
  • Lorna Parker

    Non-Executive Director

    • Tenure: 4.9yrs
  • Tom McLellan

    Non-Executive Director

    • Tenure: 4.9yrs
  • Mark Crossley

    Chief Financial & Operations Officer and Executive Director

    • Tenure: 2.7yrs
    • Compensation: US$550.80k

Company Information

Indivior PLC's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Indivior PLC
  • Ticker: INDV
  • Exchange: LSE
  • Founded: 2014
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£396.790m
  • Shares outstanding: 730.74m
  • Website: https://www.indivior.com

Number of Employees


Location

  • Indivior PLC
  • 10710 Midlothian Turnpike
  • North Chesterfield
  • Virginia
  • 23235
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
INDVLSE (London Stock Exchange)YesOrdinary SharesGBGBPDec 2014
INDVLBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBGBPDec 2014
IZQV.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDDec 2014
INVV.YOTCPK (Pink Sheets LLC)SPON ADR EA REPR 5 ORDUSUSDDec 2014
2IVADB (Deutsche Boerse AG)SPON ADR EA REPR 5 ORDDEEURDec 2014

Biography

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company’s product pipeline focuses on trea ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/16 21:34
End of Day Share Price2019/10/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.